Lundbeck has gained orphan drug designation (ODD) from Japan’s Ministry of Health, Labor and Welfare (MHLW) for amlenetug to ...

The global orphan drug market size was USD 154.20 Billion in 2022 and is expected to register a rapid revenue CAGR of 12.3 % ...

Ionis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales.

2024年5月，嘉越医药与ERASCA公司达成3.45亿美元全球授权协议，后者将开展名为AURORAS-1的国际多中心临床试验。该突破标志着我国在攻克RAS靶点领域进入国际创新梯队，有望为全球数百万RAS突变癌症患者提供新治疗方案。

VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a ...

Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy: Denmark Tuesday, March 11, 2025, 11:00 Hrs [IST] H. Lundbeck A/S (Lundbec ...

Plus Therapeutics (NASDAQ:PSTV) shares rose 71% after the company said on Thursday that the U.S. FDA has granted Orphan Drug ...

The European orphan drug market is growing and is already comparable in size and scope to the US market. The European Union ...

The FDA granted orphan drug status to rhenium-186 obisbemeda for treating leptomeningeal metastases in lung cancer.

Plus Therapeutics (PSTV) announces that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Rhenium Obisbemeda for the ...

HealthCare Pharmaceuticals was granted FDA orphan designation for a treatment of non-small cell lung cancer harboring epidermal ...